×
About 17,163 results

AFib Risk Rises as A1c Increases
https://www.medscape.com/viewarticle/984714

Nov 29th, 2022 - Researchers published the study covered in this summary on Research Square as a preprint that has not yet been peer reviewed. Key Takeaways Adults not receiving glucose-lowering drugs showed a stepwise, increasing risk of developing atrial fibrillation (AFib) that tracked with increasing levels of A1c from 5.8% to 7.6% (40 to 60 mmol/mol). Patients with new-onset diabetes had a similar risk of ...

Adding Salt to Food Linked to Higher CVD Risk
https://www.medscape.com/viewarticle/984718

Nov 29th, 2022 - A lower frequency of adding salt to food is associated with lower risk of cardiovascular disease, particularly heart failure and ischemic heart disease, a new study has found. The study analyzed the association of adding salt to food and incident cardiovascular disease risk in 176,570 adults participating in the UK Biobank database. Results showed that a lower frequency of adding salt to foods ...

We Have an Amputation Epidemic
https://www.medscape.com/viewarticle/984461

Nov 29th, 2022 - Every three minutes in America, a person loses all or part of a limb due to their diabetes. Every. Three. Minutes. Robert A. Gabbay, MD, PhD Five-year mortality numbers for individuals undergoing a diabetes-related amputation rival those of many forms of cancer. Tragically, your odds of suffering from limb loss can come down to the color of your skin, your gender, your educational level, where ...

ADHD Meds and Cardiovascular Safety: New Data
https://www.medscape.com/viewarticle/984666

Nov 28th, 2022 - A new study provides some reassurance regarding the cardiovascular safety of medications used to treat attention-deficit/hyperactivity disorder (ADHD). A large meta-analysis showed no statistically significant association between use of stimulant or nonstimulant ADHD medications and any cardiovascular disease (CVD) outcome across age groups. However, a "modest" increase in risk could not be rul...

Nov 18, 2022 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/984166

Nov 18th, 2022 - Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. In This Week’s Podcast For the week ending Novem...

Patient App Aids Decisions on Anticoagulants: ENHANCE-AF 
https://www.medscape.com/viewarticle/984253

Nov 17th, 2022 - Use of a novel "shared decision-making tool" resulted in a higher rate of patient satisfaction over the decision on whether to take oral anticoagulants for stroke prevention in atrial fibrillation (AF), a new study shows. The ENHANCE-AF study was presented November 7 at the American Heart Association (AHA) Scientific Sessions 2022 by Paul Wang, MD, professor of medicine at Stanford University S...

Spirituality an Important Coping Mechanism for Neurologic Disease
https://www.medscape.com/viewarticle/984158

Nov 16th, 2022 - Spirituality is linked to higher quality of life (QOL) and emotional well-being for patients with neurologic disorders ― and may even be associated with a lower incidence of neurologic conditions such as Alzheimer's disease (AD), new research suggests. In a review of 13 studies, investigators found that spirituality and religiosity were closely related to better QOL and emotional well-being. In...

Preeclampsia Linked to Increased Risk for Heart Disease, Stroke in Offspring
https://www.medscape.com/viewarticle/984060

Nov 15th, 2022 - Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, affecting as many as 5% of pregnancies worldwide. New evidence suggests that the complication doesn't end with delivery. Children born to women who experience preeclampsia are roughly one-third more likely to develop cardiovascular disease later in life than those not exposed to the condition, researchers have foun...

The Role of Percutaneous LAA Closure in Stroke Risk Management for Patients With AF
https://www.medscape.com/viewarticle/982006

Nov 15th, 2022 - This transcript has been edited for clarity. Ashish A. Bhimani, MD, FHRS: Hello. My name is Ashish Bhimani. I'm one of the electrophysiologists at the Piedmont Heart Institute in Atlanta. I'm joined here today by one of my partners, Dr Sandeep Goyal. I'll let him introduce himself. Sandeep K. Goyal, MD, FHRS: Hello. I'm Sandeep Goyal. I'm a cardiac electrophysiologist and medical director of th...

'COVID-22' Case Studies: What Can We Learn From Them?
https://www.medscape.com/viewarticle/984070

Nov 15th, 2022 - We’re once again seeing patients in hospital with severe cases of COVID-19, despite being triple vaccinated and not being immunocompromised. Colas Tcherakian, MD, respiratory medicine specialist at the Foch Hospital, Paris, France, presents two recent COVID case studies and explains why this new wave is similar to the first. What lessons can be learned? This transcript has been edited for clari...

Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview
https://www.medscape.com/viewarticle/983474

Nov 14th, 2022 - This transcript has been edited for clarity. John M. Mandrola, MD: Hi, everyone. This is John Mandrola from theheart.org | Medscape Cardiology. I'm here in Chicago at the American Heart Association meeting, and I'm pleased to be with my colleague, Dr Jason Andrade, from the University of British Columbia, who presented a late-breaking clinical trial today called PROGRESSIVE-AF that was also pub...

Flu Vaccination Associated With Reduced Stroke Risk
https://www.medscape.com/viewarticle/983953

Nov 11th, 2022 - Dr Jessalyn Holodinsky Influenza vaccination is associated with a reduced risk of stroke among adults, even if they aren't at high risk for stroke, according to new research. The risk of stroke was about 23% lower in the 6 months following a flu shot, regardless of the patient's age, sex, or underlying health conditions. "There is an established link between upper respiratory infection and both...

COVID May Complicate Ischemic Stroke Revascularization
https://www.medscape.com/viewarticle/983911

Nov 11th, 2022 - New data from the Global COVID-19 Stroke Registry suggest higher rates of intracranial bleeding complications and worse outcomes of stroke revascularization in acute ischemic stroke (AIS) complicated by COVID-19. However, study investigator João Pedro Marto, MD, with Hospital de Egas Moniz, Lisbon, Portugal, cautioned that the number of patients who experienced complications was small. "We beli...

BRIGHT-4: Is Bivalirudin Poised for a Comeback in STEMI PCI?
https://www.medscape.com/viewarticle/983883

Nov 10th, 2022 - The 6000-patient BRIGHT-4 trial from China is prompting a rethink on bivalirudin in cath labs around the world and whether it should be the first-choice anticoagulant in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Results show that a bivalirudin bolus followed by a 2- to 4-hour high-dose infusion reduced all-cause mortality or major b...

No Benefit of Rivaroxaban in COVID Outpatients: PREVENT-HD
https://www.medscape.com/viewarticle/983877

Nov 10th, 2022 - A new US randomized trial has failed to show benefit of a 35-day course of oral anticoagulation with rivaroxaban for the prevention of thrombotic events in outpatients with symptomatic COVID-19. The PREVENT-HD trial was presented at the American Heart Association (AHA) Scientific Sessions 2022 by Gregory Piazza, MD, Brigham and Women's Hospital, Boston, Massachusetts. "With the caveat that the ...

Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI
https://www.medscape.com/viewarticle/983619

Nov 6th, 2022 - The traditional Chinese herbal medicine tongxinluo added to guideline-directed therapy improves clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI), the CTS-AMI study suggests. Compared with placebo, Chinese patients assigned to tongxinluo had lower rates of 30-day and 1-year major adverse cardiovascular and cerebrovascular events (MACCE), driven by fewer cardi...

Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS
https://www.medscape.com/viewarticle/983618

Nov 6th, 2022 - Routine early, expeditious use of extracorporeal membrane oxygenation (ECMO) is a common strategy in patients with severe cardiogenic shock, but a less aggressive initial approach may be just as effective, a randomized trial suggests. In the study that assigned patients with "rapidly deteriorating or severe" cardiogenic shock to one or the other approach, clinical outcomes were no better for th...

New Trial Suggests CV Benefit With EPA: RESPECT-EPA
https://www.medscape.com/viewarticle/983621

Nov 6th, 2022 - A new Japanese study of highly purified eicosapentaenoic acid (EPA; icosapent ethyl) has suggested a possible benefit in reducing adverse cardiovascular events in patients with chronic coronary artery disease taking statins. The open-label randomized RESPECT-EPA study showed a reduction of borderline statistical significance in its primary endpoint of a composite of cardiovascular death, nonfat...

Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP
https://www.medscape.com/viewarticle/983608

Nov 5th, 2022 - There was no difference in major cardiovascular outcomes with the use of two different diuretics — chlorthalidone or hydrochlorothiazide — in the treatment of hypertension in a new large randomized real-world study. The Diuretic Comparison Project (DCP), which was conducted in more than 13,500 U.S. veterans age 65 years or over, showed almost identical rates of the primary composite endpoint, i...

HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science
https://www.medscape.com/viewarticle/983614

Nov 5th, 2022 - U.S. experts favor chlorthalidone over hydrochlorothiazide (HCTZ) in the first-line treatment of hypertension. Yet practicing doctors are approximately 20-fold more likely to choose HCTZ over chlorthalidone.  During the opening late-breaking clinical trials session here at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, we learned that practicing doctors had it right. ...